<DOC>
	<DOCNO>NCT01515657</DOCNO>
	<brief_summary>This study determine aspirin PL2200 , investigational product , get blood stream quickly plain aspirin enteric coat aspirin , test whether PL2200 able prevent blood clot effectively product , administer patient diabetes .</brief_summary>
	<brief_title>Pharmacodynamic Evaluation PL2200 Versus Enteric-Coated Immediate Release Aspirin Diabetic Patients</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Aspirin</mesh_term>
	<criteria>Adults 2179 Body mass index ( BMI ) 3040 kg/m2 Noninsulindependent type2 diabetic ( confirm hemoglobin A1c ( HbA1c ) &gt; 6.4 % and/or fast plasma glucose &gt; 125 mg/dL current antidiabetic medication ) AAinduced platelet aggregation response &gt; 60 % within 3 hour prior initial dose study drug administration Contraindications aspirin Previous history vascular disease Patient require insulin Use nonsteroidal antiinflammatory drug , antisecretory agent , antacid , salicylatecontaining nutritional supplement within 2 week randomization</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>